A new publication involving protirelin appeared on August 20, 2026, in the journal Pituitary. The study is titled "Diagnostic value of the TRH test for central hypothyroidism in patients with pituitary and parasellar tumors: a single-center retrospective cross-sectional study." It is described as a single-center retrospective cross-sectional study. The publication focuses on the TRH test, which uses protirelin, in the context of central hypothyroidism diagnosis. The study population included patients with pituitary and parasellar tumors. This is a retrospective analysis based at a single medical center, as stated in the publication title.
No specific findings, results, or conclusions from the study are included in this brief. This report reflects only the availability of the new publication and its stated scope. Readers interested in the details of the diagnostic value assessed should consult the full text through the linked source. Protirelin remains an approved compound used in TRH testing protocols. For general background on protirelin and its approved uses, readers can consult the compound overview.